We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Proteros and SUPERGEN Enter Into an Integrated Lead Discovery Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros and SUPERGEN Enter Into an Integrated Lead Discovery Agreement"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Proteros Biostructures GmbH (Proteros) announced that it has entered into an agreement with SuperGen Inc., under which Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest.

Under the agreement, Proteros will deploy its integrated lead discovery platform that seamlessly links structural biology, screening of a tailor-made compound and fragment library, compound profiling and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.

Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by SuperGen to work with them on an exciting target. We believe our structure guided approach is particularly suited to accelerate SuperGen’s efforts in this target area.”

“Rapid fragment evaluation will synchronize well with our CLIMB® discovery platform” said Dr. Michael McCullar, Senior Vice President Strategy and Discovery Operations “We are excited to be working with Proteros”.